Clinical Trials
59 trialsCabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3)
Johannes Gutenberg University Mainz
Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma
Jiangsu Cancer Institute & Hospital
Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations
Seoul St. Mary's Hospital
[18F]FPIA
University College, London
A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer
Second Affiliated Hospital of Soochow University
BRISK
Asan Medical Center
Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors
Second Affiliated Hospital of Soochow University
IMPARP-HRD
Peter MacCallum Cancer Centre, Australia
ExeNTrO
Radboud University Medical Center
CaEP-R
Zealand University Hospital
ADVANCE-II
Mendus
PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.
Second Affiliated Hospital of Soochow University
Patients With Refractory, Metastatic Cancer Harboring KIT Mutation or Amplification to Investigate the Clinical Efficacy and Safety of Imatinib Therapy
Samsung Medical Center
Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011)
Dr. Frank Arguello Cancer Clinic
Efficacy and Safety of Precision Therapy in Refractory Tumor
Shanghai Changzheng Hospital
Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary
Shanghai Changzheng Hospital
ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0)
Second Affiliated Hospital of Soochow University
Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA)
National University Hospital, Singapore
Safety and Efficacy of PEG-rhG-CSF in Preventing Neutropenia in Children With Tumor After Chemotherapy
Sun Yat-sen University
REBORN
Tetra Bio-Pharma
Drug Repurposing for the Prevention of Chemotherapy-induced Peripheral Neuropathy (CIPN)
Cairo University
AVATAR
Hospital Universitario de Fuenlabrada
A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers
Korean Cancer Study Group
High Resolution Microendoscopy for the Detection of Esophageal Squamous Cell Neoplasia
Anandasabapathy, Sharmila, M.D.
MentorA1
Associacao de Investigacao de Cuidados de Suporte em Oncologia
Arsenic Trioxide for Structural p53 Mutations
Shanghai Changzheng Hospital
TIDE-A
Consorzio Oncotech
Tepotinib in Solid Tumors Harboring MET Alterations
Chungbuk National University Hospital
Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma
Shanghai Junshi Bioscience Co., Ltd.
A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma
National University Hospital, Singapore
CheCUP
University Hospital Heidelberg
Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
TOPARP
Institute of Cancer Research, United Kingdom
NICE-COMBO
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor
Haining Health-Coming Biotech Co., Ltd.
PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS/NRAS Mutation or no Actionable Genetic Abnormalities
Asan Medical Center
Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation
Asan Medical Center
HERZUMA-GC
Dong-A University Hospital
Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation
Asan Medical Center
Afatinib Plus Chemotherapy Against Esophageal or Lung Squamous Cell Carcinoma
Fujian Cancer Hospital
Icotinib Combined With Dihydroaremisinin (DHA) Therapy in Patients With Advanced NSCLC
Peking University Cancer Hospital & Institute
TK3bFIIABC
Faculdade de Medicina do ABC
Phase IIa Dose-Expansion and Biomarker Study of OPB-111077
National University Hospital, Singapore
ROSETTA
Technical University of Munich
Phase 2 Study of Gemcitabine and Docetaxel Combination Chemotherapy in Patients With Carcinoma of Unknown Primary
Samsung Medical Center
FURVA
Velindre NHS Trust
Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma
Biotech Pharmaceutical Co., Ltd.
The Optimization of 5-Fluorouracil Dose by Pharmacokinetic Monitoring in Asian Patients With Advanced Stage Cancer
National University Hospital, Singapore
A Randomized Study of Olanzapine for the Prevention of CINV in Patients Receiving Moderately Emetogenic Chemotherapy
Korean South West Oncology Group
Bromelain, Comosain as a New Drug for Treating and Preventing Various Types of Cancer in the Humans
Oeyama-Moto Cancer Research Foundation